Diagnostic Siginificance Of Plasma LncRNA-GAS5 And LncRNA-CCAT1 Expression In Non-small Cell Lung Cancer

Objective:To explore the clinical diagnostic value of lncRNA-GAS5 and lncRNA-CCAT1 for non-small cell lung cancer(NSCLC)by detecting the expression levels of these two lncRNAs in patients with NSCLC and benign lung disease in plsama.METHODS:1.Research objects: Plasma samples from 60 patients with untreated NSCLC and 60 benign lung diseases were collected clinically,and 20 normal human peripheral blood samples were collected for proofreading of plasma lncRNAs.2.Research ideas: The collected peripheral blood samples were processed to obtain plasma samples,extracted by plasma total RNA,cDNA synthesis,and finally the relative expression levels of lncRNA-GAS5 and lncRNA-CCAT1 in plasma were detected by real-time PCR.To compare the expression differences between the two lncRNAs in the patients with NSCLC and benign lung disease,and the correlations between their expression levels and clinicopathological features of patients in NSCLC were analyzed.3.Statistical analysis: The measured lncRNA-GAS5 and lncRNA-CCAT1 data were analyzed using SPSS22.0 statistical software,and the obtained data were expressed as mean ±standard deviation.Based on the data obtained,a receiver operating characteristic(ROC)curve was constructed to evaluate the efficacy of these two types of lncRNAs in the diagnosis of NSCLC.The cut off values of lncRNA-GAS5 and lncRNA-CCAT1 for the diagnosis of NSCLC were determined according to the ROC curve.The sensitivity,specificity,accuracy,positive predictive value and negative predictive value for the diagnosis of NSCLC alone and in combination were calculated,and compared with the classical tumor markers carcinoembryonic antigen(CEA)and cytokeratin 19(Cyfra21-1).RESULTS:1.Real-time PCR showed that the relative expression levels of plasma lncRNA-GAS5 in patients with NSCLC and patients with benign lung disease were 0.149±0.094 and 0.303±0.207,the expression of lncRNA-GAS5 in plasma of NSCLC patients was down-regulatedcompared with benign lung disease group(t=-0.379,P<0.05),the difference was statistically significant(P<0.05).The relative expression of plsama lncRNA-CCAT1 in patients with NSCLC and patients with benign lung disease was 4.695±1.367 and 3.406±1.325,the expression of lncRNA-CCAT1 in plasma of NSCLC patients was down-regulated compared with benign lung disease group(t=5.721,P<0.05).The difference was statistically significant(P<0.05).2.There was a correlation between plasma lncRNA-GAS5 expression and smoking history of NSCLC patients(P<0.05),but there was no correlation between plasma lncRNA-GAS5 expression and gender,age,tissue classification and clinical stage of NSCLC patients(P>0.05).Plasma lncRNA-CCAT1 expression were not associated with gender,age,smoking history,tissue type,and clinical stage of NSCLC patients(P>0.05).3.The area under the ROC curve(AUC)of plasma lncRNA-GAS5 and lncRNA-CCAT1 for the diagnosis of NSCLC was 0.772(95% CI:0.69~0.855)and 0.762(95% CI:0.678~0.846),higher than CEA and Cyfra21-1(0.737 and 0.735).The sensitivity of plasma lncRNA-GAS5 and lncRNA-CCAT1 for the diagnosis of NSCLC was 86.7% and 88.3%,respectively,higher than CEA and Cyfra21-1(66.7% and 45.0%).4.When plasma lncRNA-GAS5 and lncRNA-CCAT1 were combined to diagnose NSCLC,the AUC was 0.772.Compared with the diagnosis alone,the sensitivity increased to 91.7%,but the specificity decreased slightly.Conclusion:1.Plasma lncRNA-GAS5 and lncRNA-CCAT1 are more sensitive to the diagnosis of NSCLC than CEA and Cyfra21-1.2.Combined detection of these two lncRNAs for diagnosis of NSCLC has a higher sensitivity of diagnosis than single-item testing.